Article
Identification of drug resistance mechanisms induced in response to KRAS therapeutics
2021-01-01
Abstract excerpt
KRAS is one of the most frequently mutated oncogenes in cancer and exhibits high prevalence in pancreatic, colon and lung cancers. The development of effective KRAS therapeutics has been challenging and only in recent years have promising targeted KRAS inhibitors been developed, including those that specifically target the oncogenic KRAS-G12C mutant commonly found in nonsmall cell lung cancer (NSCLC). As with most...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 691f43e1-ddfe-5d18-afdf-c263fad23bc0
- DOI
- 10.17638/03140729